Cervix
- Home
- Cancer Infomation
Comprehensive Clinical Guide: Cervical Cancer
Cervical cancer remains a primary focus of global oncology due to its high preventability and the definitive role of persistent Human Papillomavirus (HPV) infection. Clinical management has been refined by the widespread adoption of primary HPV screening, the integration of immunotherapy into first-line settings, and a selective return to open surgical techniques for early-stage disease to optimize oncological outcomes.
Etiology & Risk Factors
The oncogenesis of cervical cancer is almost exclusively driven by high-risk HPV types, which integrate into the host genome and disrupt cell cycle regulation.
Primary Cause (HPV):
- Over 95% of cases are caused by persistent infection with high-risk HPV. HPV 16 and 18 are responsible for ~70% of all cases.
Environmental & Lifestyle Triggers:
- Tobacco Smoking: Carcinogens concentrated in cervical mucus double the risk of progression from infection to malignancy.
- Immunosuppression: Women living with HIV are six times more likely to develop cervical cancer.
- Long-term Oral Contraceptive (OCP) Use: Associated with a slight increase in risk.
Genetic Predispositions:
- While not a classic "hereditary" cancer like breast or ovarian, polymorphisms in HLA class II genes and the TP53 codon 72 may influence an individual's ability to clear HPV infections.
Clinical Manifestations
Cervical cancer typically progresses slowly from pre-invasive lesions (CIN) to invasive carcinoma, offering a wide window for intervention.
Early-Stage Symptoms:
- Post-coital Bleeding: The most specific early warning sign.
- Intermenstrual Bleeding (Metrorrhagia): Irregular spotting between periods.
- Abnormal Vaginal Discharge: May be watery, mucoid, or slightly blood-tinged.
Advanced-Stage Symptoms:
- Pelvic or Low Back Pain: Indicative of parametrial or pelvic wall involvement.
- Leg Edema (Unilateral): Suggestive of lymphatic or venous obstruction by pelvic lymph nodes.
- Hydronephrosis: Ureteral compression leading to renal dysfunction (Stage IIIB/IVA).
- Hematochezia or Hematuria: Signifying invasion into the rectum or bladder.
Paraneoplastic Syndromes:
Rare, but can include Hypercalcemia (due to PTHrP) or Hypertrophic Osteoarthropathy.
Diagnostic Workup
The pathway has shifted toward “Primary HPV Screening” as the most sensitive first step.
- Colposcopy & Directed Biopsy: Triggered by abnormal screening. Use of Acetic Acid and Lugol’s Iodine helps identify acetowhite lesions and iodine-negative areas.
- LLETZ / Cone Biopsy: Necessary if colposcopy is unsatisfactory or if microinvasive disease (Stage IA) is suspected to evaluate the depth of invasion and margin status.
- Biomarker Testing: IHC for p16INK4a (a surrogate marker for high-risk HPV activity) and PD-L1 (CPS score) to determine eligibility for immunotherapy.
- Liquid Biopsies: Circulating HPV-DNA (cHPV-DNA) is used as a highly sensitive marker for monitoring minimal residual disease (MRD) after definitive chemoradiation.
Common Investigations & Staging
Staging for cervical cancer is primarily clinical, the AJCC Version 9 / UICC 9th Edition (aligned with FIGO 2018/2023) allows for the integration of high-quality imaging.
Imaging Modalities & Rationale
- Pelvic MRI (Multiparametric): The gold standard for local staging. It provides the highest resolution for assessing stromal invasion, tumor size, and parametrial involvement.
- Whole-Body FDG PET-CT: Mandatory for Stage IB2 and higher. It is the most sensitive modality for detecting extrapelvic lymph node metastasis (para-aortic) and distant spread.
Treatment Overview
Comprehensive Treatment Approaches for Cervical Cancer (Surgery, Radiotherapy, and Systemic Therapy)
1. Surgery
- Radical Trachelectomy: An organ-sparing approach for young patients wishing to preserve fertility (Stage IA2–IB1, tumor <2cm).
- Radical Hysterectomy (Type B/C): For Early Stage where fertility preservation is not desired.
- Open Radical Hysterectomy is the standard of care. Minimally invasive (Robotic/Laparoscopic) approaches are reserved for highly selected cases.
- Exenteration: A radical "salvage" procedure for central pelvic recurrence.
2. Radiotherapy
- Definitive Chemoradiation (CCRT) or Induction Chemotherapy/Immunotherapy with Radiotherapy: The standard for locally advanced stage.
3. Systemic Therapy
- First-Line (Metastatic/Recurrent): The "Triplet" or "Quadruplet" regimen: Platinum + Paclitaxel + Bevacizumab ± Pembrolizumab (for PD-L1 positive tumors).
- Antibody-Drug Conjugates (ADCs): Tisotumab vedotin (targeting Tissue Factor) is a standard second-line option.
- Immunotherapy: Checkpoint inhibitors (Pembrolizumab, Cemiplimab) are now used both in the metastatic setting and following CCRT in high-risk patients.
Emerging Therapies
- Therapeutic HPV Vaccines: DNA-based vaccines (e.g., VGX-3100) are in late-stage trials to induce a T-cell response against E6/E7, potentially reversing high-grade CIN without surgery.
- Adoptive Cell Therapy (ACT): Utilizing Tumor-Infiltrating Lymphocytes (TILs) specifically reactive to HPV oncoproteins for patients who have failed multiple lines of chemotherapy.
- AI-Enhanced Colposcopy: Deep-learning algorithms are now used during colposcopy to provide a "second opinion" on biopsy sites, increasing the detection rate of occult high-grade disease.
Medical Disclaimer
Treatment must be individualized by a multidisciplinary team (MDT).
Standards reflect the 2026 oncology landscape; always consult the latest NCCN, FIGO, or institutional guidelines.